Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MITF | O75030 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ACP3 | P15309 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215589 | 0.91 | CES2 (0.57) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL28418656 | 0.89 | MAPT (0.56) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL6642403 | 0.86 | NPC1 (0.63) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL17637163 | 0.86 | NPC1 (0.53) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL7560417 | 0.86 | L3MBTL1 (0.66) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL23674188 | 0.85 | NPC1 (0.61) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL812736 | 0.84 | LMNA (0.67) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL4604321 | 0.84 | MAPT (0.61) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL29262742 | 0.84 | LMNA (0.67) | MAPTNPC1RAB9APOLBKMT2A | |
| SCHEMBL4604318 | 0.84 | MAPT (0.61) | MAPTNPC1RAB9APOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5789576-A | DIASTEREOSPECIFIC DIMERIZATION USING ALKOXYMAGNESIUM HALIDE REACTANT; USED FOR SOLID PHASE SYNTHESIS OF ANTISENSE OLIGONUCLEOTIDES | GENTA INCORPORATED (US) | 1998-08-04 | — | — | US | claimed |
| US-5166330-A | Phosphonation, amination and reaction with nucleosides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-24 | — | — | US | claimed |
| EP-0136543-B1 | METHOD FOR THE PREPARATION OF NUCLEOSIDEALKYL, ARALKYL AND ARYL PHOSPHONITES AND PHOSPHONATES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-23 | — | — | EP | claimed |
| EP-0136543-A2 | Method for the preparation of nucleosidealkyl, aralkyl and aryl phosphonites and phosphonates | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-10 | — | — | EP | claimed |
| US-RE39708-E1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-0592434-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERS | GENTA INC (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0592434-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERS | GENTA INCORPORATED (US) | 1994-04-20 | — | — | EP | disclosed |
| EP-0554407-A4 | — | — | 1994-04-13 | — | — | EP | disclosed |
| EP-0554407-A1 | NON-AROMATIC ORGANIC POLYMERIC REAGENTS FOR SOLID PHASE SYNTHESIS OF OLIGOMERS | GENTA INCORPORATED (US) | 1993-08-11 | — | — | EP | disclosed |
| US-5166330-A | Phosphonation, amination and reaction with nucleosides | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-24 | — | — | US | disclosed |
| WO-1992007882-A1 | NON-AROMATIC ORGANIC POLYMERIC REAGENTS FOR SOLID PHASE SYNTHESIS OF OLIGOMERS | GENTA INCORPORATED (US) | 1992-05-14 | — | — | WO | disclosed |
| WO-1992007864-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERS | GENTA INCORPORATED (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0136543-B1 | METHOD FOR THE PREPARATION OF NUCLEOSIDEALKYL, ARALKYL AND ARYL PHOSPHONITES AND PHOSPHONATES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-23 | — | — | EP | disclosed |
| EP-0136543-A2 | Method for the preparation of nucleosidealkyl, aralkyl and aryl phosphonites and phosphonates | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | MAPT 1269/4885NPC1 954/4885RAB9A 2665/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | MAPT 1269/4885NPC1 954/4885RAB9A 2665/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | MAPT 1269/4885NPC1 954/4885RAB9A 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.